ERBB2 and gastric cancer: The demonstrated HER2+ rate in gastric/gastroesophageal junction cancer ranges from 4.4% to 53.4%, and 22% of gastric cancer patients have high HER-2 expression, and about 24% of gastric cancer patients have low HER-2 expression.